NEW YORK – California-based A2 Biotherapeutics will begin clinical development of its T-cell module platform, called Tmod, after raising $71.5 million in funding.
Existing investors, including The Column Group, Vida Ventures, Samsara BioCapita, and Nextech Invest, participated in the Series B funding round, along with new investors Casdin Capital, Euclidean Capital, UC Investments (Office of the Chief Investment Officer of the Regents), and Hartford HealthCare Endowment.